<SEC-DOCUMENT>0001213900-26-063825.txt : 20260602
<SEC-HEADER>0001213900-26-063825.hdr.sgml : 20260602
<ACCEPTANCE-DATETIME>20260602090434
ACCESSION NUMBER:		0001213900-26-063825
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20260602
DATE AS OF CHANGE:		20260602

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			KAZIA THERAPEUTICS LTD
		CENTRAL INDEX KEY:			0001075880
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-292303
		FILM NUMBER:		261053822

	BUSINESS ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		THREE INTERNATIONAL TOWERS LEVEL 24,
		STREET 2:		300 BARANGAROO AVENUE
		CITY:			SYDNEY NSW
		PROVINCE COUNTRY:   	C3
		ZIP:			2000
		BUSINESS PHONE:		01161298780088

	MAIL ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		THREE INTERNATIONAL TOWERS LEVEL 24,
		STREET 2:		300 BARANGAROO AVENUE
		CITY:			SYDNEY NSW
		PROVINCE COUNTRY:   	C3
		ZIP:			2000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NOVOGEN LTD
		DATE OF NAME CHANGE:	19981228
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>ea029311505-424b3_kazia.htm
<DESCRIPTION>PROSPECTUS SUPPLEMENT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Filed Pursuant to Rule 424(b)(3)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Registration No. 333-292303 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>PROSPECTUS SUPPLEMENT </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>(to Prospectus dated December 23, 2025) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>10,700,211 American Depositary Shares representing
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>5,350,105,500 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Ordinary Shares </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="ea029311505_img1.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Kazia Therapeutics Limited</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This prospectus supplement is being filed to update and supplement
the information contained in the prospectus dated December 23, 2025 (the &ldquo;Prospectus&rdquo;), which forms a part of our Registration
Statement on Form F-1 (Registration No. 333-292303), with the information contained in our current report on Form 6-K, furnished to the
Securities and Exchange Commission on June 2, 2026 (the &ldquo;June 2, 2026 Form 6-K&rdquo;). Accordingly, we have attached the June 2,
2026 Form 6-K to this prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This prospectus supplement updates and supplements the information
in the Prospectus and is not complete without, and may not be delivered or utilized except in combination with, the Prospectus, including
any amendments or supplements thereto. This prospectus supplement should be read in conjunction with the Prospectus and if there is any
inconsistency between the information in the Prospectus and this prospectus supplement, you should rely on the information in this prospectus
supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The ADSs are listed on The Nasdaq Capital Market (&ldquo;Nasdaq&rdquo;)
under the symbol &ldquo;KZIA.&rdquo; On June 1, 2026, the last reported sale price of the ADSs on Nasdaq was $12.56 per ADS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Investing in our securities involves a high degree of risk. See
&ldquo;Risk Factors&rdquo; beginning on page 9 of the Prospectus and the &ldquo;Risk Factors&rdquo; in &ldquo;Item 3. Key Information-D.
Risk Factors&rdquo; of our most recent Annual Report on Form 20-F, which is incorporated by reference in the Prospectus, as well as in
any other recently filed reports and, if any, in any applicable prospectus supplement. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Neither the Securities and Exchange Commission nor any state securities
commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of the Prospectus or this prospectus
supplement. Any representation to the contrary is a criminal offense. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>The date of this prospectus supplement is June
2, 2026</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>WASHINGTON, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 6-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REPORT OF FOREIGN PRIVATE ISSUER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO RULE 13a-16 OR 15d-16</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>For the Month of June 2026</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Commission File Number: 000-29962</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Kazia Therapeutics Limited.&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact Name of Registrant as Specified in Its Charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Three International Towers Level 24 300 Barangaroo
Avenue Sydney NSW 2000 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Form 20-F &#9746; <B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</B>Form 40-F &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INFORMATION CONTAINED IN THIS FORM 6-K REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Appointment of Chief Financial Officer</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This report on Form 6-K (the &ldquo;Report&rdquo;) contains information
regarding the appointment of a new executive officer of Kazia Therapeutics Limited (the &ldquo;Company&rdquo;). On June 2, 2026, the Company
announced the appointment of James Levine as Chief Financial Officer, effective June 1, 2026.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In connection with Mr. Levine&rsquo;s appointment, the Company&rsquo;s
subsidiary, Kazia Therapeutics, Inc., entered into an employment letter agreement with Mr. Levine, effective June 1, 2026 (the &ldquo;Employment
Agreement&rdquo;). Mr. Levine will receive an annual base salary of US$475,000, is eligible for an annual target bonus of 40% of his annual
base salary (prorated for 2026), and, subject to Board approval, will be granted options over 200,000 American Depositary Shares (&ldquo;ADSs&rdquo;).
One-third of the ADS options will vest upon commencement of employment, with the remaining two-thirds vesting in equal yearly installments
thereafter. Mr. Levine will forfeit all options upon a voluntary departure prior to the completion of one year of employment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Mr. Levine&rsquo;s employment is on an at-will basis. In the event
of a termination without Cause or resignation for Good Reason (each as defined in the Employment Agreement) in connection with a Change
in Control (as defined in the Employment Agreement), Mr. Levine is entitled to (i) severance pay equal to 12 months of base salary, (ii)
a pro-rata bonus for the year of termination, and (iii) continued health care coverage under COBRA for up to 6 months. In the event of
a termination without Cause or resignation for Good Reason other than in connection with a Change in Control, Mr. Levine is entitled to
(i) severance pay equal to a maximum of 6 months of base salary (subject to mitigation), (ii) a pro-rata bonus for the year of termination,
and (iii) continued health care coverage under COBRA for up to 6 months. Receipt of severance benefits is conditioned upon Mr. Levine&rsquo;s
compliance with the confidentiality and proprietary information agreements, as well as his delivery of an effective general release of
claims within 30 days following termination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Employment Agreement also contains customary provisions regarding
confidentiality, assignment of inventions, and a 12-month post-termination non-solicitation covenant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The foregoing summary of the Employment Agreement does not purport
to be complete and is qualified in its entirety by reference to the full text of the Agreement, which is filed as Exhibit 10.1 to this
Report and is incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Press Release</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company is furnishing with this Report on Form 6-K a press release
announcing the appointment of Mr. Levine, dated June 2, 2026, as Exhibit 99.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Incorporation by Reference</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company hereby incorporates by reference the information contained
herein, including Exhibits 10.1 and 99.1, except for the quotes of Dr. John Friend, Chief Executive Officer of the Company, contained
in Exhibit 99.1, into the Company&rsquo;s registration statements on Form F-3 (File Nos. <A HREF="https://www.sec.gov/Archives/edgar/data/1075880/000119312523296811/d866423df3.htm" STYLE="-sec-extract: exhibit">333-276091</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1075880/000119312524213396/d867638df3.htm" STYLE="-sec-extract: exhibit">333-281937</A> and <A HREF="https://www.sec.gov/Archives/edgar/data/1075880/000121390026029366/ea0281732-f3_kazia.htm" STYLE="-sec-extract: exhibit">333-294392</A>).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following exhibits are furnished as part of this Form 6-K:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 9%; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 90%; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_001">Employment Agreement, dated as of June 1, 2026, by and between Kazia Therapeutics, Inc. and James Levine.</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_002">Press Release dated June 2, 2026.</A></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Kazia Therapeutics Limited.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 35%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ John Friend</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">John Friend</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: June 2, 2026</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_001"></A>Exhibit
10.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><IMG SRC="ea029311505_img2.jpg" ALT=""><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
1, 2026</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">James Levine</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">San Diego, CA</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dear
James,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Offer
of Employment with Kazia Therapeutics</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
behalf of Kazia Therapeutics, Inc, I am pleased to offer you the position of <B>Chief Financial Officer</B>. We look forward to welcoming
you as a colleague.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
terms of the position are as set forth below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Position</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Particulars</U>.
Your position, place of work, and commencement date will be as described in Attachment 1 of this letter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Employer</U>.
Your employer will be Kazia Therapeutics, Inc (the &ldquo;Company&rdquo;), a Delaware company. Kazia reserves the right to assign your
employment to other corporate entities within its group at its sole discretion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Obligation
to Best Efforts</U>. You agree that you will, at all times, loyally and conscientiously perform all the duties and obligations associated
with this role to the best of your ability and experience, and to the reasonable satisfaction of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Outside
Activities; Non-Interference; Conflicts of Interest</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the term of your employment, you agree to devote your business time, attention, skill, and efforts to the business of the Company. All
benefits, profits, results, and work product arising from or incident to your services shall belong exclusively to the Company. Except
as expressly disclosed herein or approved in advance in writing by the Chief Executive Officer, you shall not render commercial or professional
services of any nature to any other person or organization, whether or not for compensation, nor shall you directly or indirectly engage
in or participate in any business that is competitive with the business of the Company. Nothing in this agreement shall prohibit you
from accepting occasional speaking or presentation engagements for customary honoraria or from serving on the boards of charitable or
non-profit organizations, provided such activities do not interfere with your duties to the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Travel
and Expenses</U>. You acknowledge that the nature of the position may require frequent travel within and outside of the United States
from time to time. The Company will make reasonable efforts to accommodate your circumstances and preferences in directing such travel.
You will be entitled to reimbursement of reasonable and customary expenses incurred in carrying out the position, in accordance with
the Company&rsquo;s policies, on submission of an expense report and valid receipts.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compensation</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Salary</U>.
Your compensation will be as itemised in Attachment 1 of this letter and paid to you once per month pursuant to the Company&rsquo;s regular
payroll policy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Performance
and Salary Review</U>. Your performance and compensation package will be reviewed no less than once annually. Any pay increases will
be made in accordance with your performance and in reference to industry compensation benchmarks for comparable positions. Adjustments
to </FONT>compensation will be at Kazia&rsquo;s sole discretion and are not guaranteed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Sole
Consideration</U>. You acknowledge that the compensation described in Attachment 1 of this letter will be your only remuneration for
your employment with the company. Due to the senior nature of the position, you acknowledge that additional hours may be required from
time to time and that no separate payment will be made for overtime. You may be requested to perform additional duties that are consistent
with your role and experience.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Equity
Participation</U>. Following your commencement, Kazia will recommend to the Board of Directors that you be granted options over the company&rsquo;s
stock, to an amount as specified in Attachment 1 of this letter. This grant is at the discretion of the Board of Directors and will be
subject to the company&rsquo;s Employee Stock Option Plan. At the discretion of the Board of Directors, you may be eligible for further
grants of stock options during the term of your employment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 6; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --> of 8</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Benefits</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Benefits</U>.
Your benefits will be as itemised in Attachment 1 of this letter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Insurance
Benefits</U>. The Company will provide a welfare benefits package which includes medical, dental, vision and other coverages, the benefits
of which are equivalent for other employees of similar position and may require an employee monthly co-payment depending upon coverage
options selected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Vacation
and Holidays</U>. You will be eligible for paid time off (PTO) as itemised in Attachment 1 of this letter. You will also receive paid
time off for US holidays observed by Kazia. Kazia&rsquo;s policies regarding vacation and holidays will be provided to you separately
on commencement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Severance</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If,
at any time, (a) the Company terminates your employment without Cause (as defined herein), and other than as a result of your death or
disability, or (b) you resign for Good Reason (as defined herein), and provided such termination constitutes a &ldquo;separation from
service&rdquo; (as defined under Treasury Regulation Section 1.409A-1(h)), you shall be entitled to receive the following severance benefits:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>if
                                            in Connection with a Change in Control</U>: you shall be entitled to (i) severance pay in
                                            the form of monthly payments equal to 12 months of your base salary in effect on the effective
                                            date of termination, (ii) a lump sum payout of a pro-rata bonus for the bonus year, based
                                            on good faith estimates of the achievement of performance goals on the date of termination,
                                            and (iii) if you timely elect continued health care coverage under COBRA, the Company shall
                                            pay the same proportion of your premium rate for you and your eligible dependents as before
                                            the date of termination or, if COBRA coverage is not available, then the Company shall reimburse
                                            you for such amount (in the same proportion as before the termination) through the earlier
                                            of (A) 6 months following the Separation from Service, or (B) the date upon which you and
                                            your eligible dependents become covered under similar plans (and you agree to notify the
                                            Company of such other coverage);</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>if
                                            other than in Connection with a Change in Control</U>: (i) subject to the requirement to
                                            mitigate below, you shall be entitled to severance pay in the form of monthly payments equal
                                            to a maximum of 6 months of your base salary in effect on the effective date of termination,
                                            (ii) a lump sum payout of a pro-rata bonus for the year, based on good faith estimates of
                                            the achievement of performance goals on the date of termination, and (iii) if you timely
                                            elect continued health care coverage under COBRA, the Company shall pay the same proportion
                                            of your premiums for you and your eligible dependents as before the date of termination or,
                                            if COBRA coverage is not available, then the Company shall reimburse you for such amount
                                            (in the same proportion as before the termination) through the earlier of (A) 6 months following
                                            the Separation from Service, or (B) the date upon which you and your eligible dependents
                                            become covered under similar plans (and you agree to notify the Company of such other coverage).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Such
severance benefits are conditional upon (a) your continuing compliance with your obligations under your Confidentiality Agreement and
Proprietary Information and Inventions Agreement; (b) your delivery to the Company of an effective general release of claims in favor
of the Company and its affiliates in a form acceptable to the Company within 30 days following your termination date. The monthly severance
payments and lump sum bonus payment will be subject to standard deductions and withholdings following termination; provided, however,
that no payments will be made prior to the 40th day following your termination. On the 40th day following your Separation from Service
date, the Company will pay you the salary continuation payments that you would have received on or prior to such date in a lump sum under
the original schedule but for the delay while waiting for the effectiveness of the release, with the balance of the cash severance and
the bonus payment being paid as originally scheduled.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
purposes of this letter, &ldquo;Cause&rdquo; means (A) your conviction (including a guilty plea or a no contest plea) of a felony, or
of any other crime involving fraud, dishonesty or moral turpitude; (B) your commission of or participation in a fraud against the Company;
(C) your material breach of any written agreement between you and the Company (including but not limited to your Proprietary Information
Agreement) or material breach of any statutory or fiduciary duty you owe to the Company, in each case that causes material harm to the
Company; or (D) your conduct that constitutes gross insubordination as reasonably determined by the Board; provided in each case that
the Company gives you written notice and 30 day opportunity to cure and to be heard by the Board before its final determination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
purposes of this letter, &ldquo;Change in Control&rdquo; means (A) where, as a result of any takeover bid, scheme of arrangement or any
other event or transaction, a person or entity becomes entitled to more than 50% of the Shares or to all or substantially all of the
Group&rsquo;s business and assets (provided that no sale or transfer undertaken in respect of an internal reorganisation of the structure,
business or assets of the Group shall constitute a Change of Control Event); or (B) any other event determined by the Board to constitute
a &ldquo;Change of Control Event&rdquo; for the purposes of these Rules (excluding, for the avoidance of doubt, an internal reorganisation
of the structure, business or assets of the Group).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> of 8</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
purposes of this letter, you shall have &ldquo;Good Reason&rdquo; for your resignation from your employment with the Company and/or
any of its subsidiaries or parent entities or successor entities if any of the following events occur without your consent:(A)
material reduction in your duties (including responsibilities and/or authorities), provided, however, that a change in job position
(including a change in title) shall not be deemed a &ldquo;material reduction&rdquo; in and of itself unless your new duties,
responsibilities and/or authorities are substantially reduced from the prior duties, responsibilities and/or authorities; (B)
relocation of your principal place of employment to a place that increases your one-way commute by more than fifty (50) miles as
compared to your then current principal place of employment immediately prior to such relocation; (C) a reduction of at least 10% of
your gross base salary (unless pursuant to a salary reduction program applicable generally to the Company&rsquo;s executive
employees); or (D) a change in your reporting line such that you report to a position subordinate to the Chief Executive Officer. To
constitute Good Reason, you must (i) give the Company written notice of the existence of the event(s) within ninety (90) days after
their occurrence; (ii) allow the Company thirty (30) days to cure the existence of the event(s); and (iii), if uncured, resign from
your employment within sixty </FONT>(60) days after the cure period has expired.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
purposes of this letter, &ldquo;in Connection with a Change in Control&rdquo; will mean if your employment is terminated during that
period either three (3) months prior to or twelve (12) months following a Change in Control.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is intended that the severance benefits payable under this letter satisfy, to the greatest extent possible, the exemptions from the application
of Internal Revenue Code Section 409A provided under Treasury Regulations 1.409A 1(b)(4), 1.409A 1(b)(5) and 1.409A 1(b)(9), and this
letter will be construed to the greatest extent possible as consistent with those provisions. For purposes of Code Section 409A (including,
without limitation, for purposes of Treasury Regulation Section 1.409A 2(b)(2)(iii)), your right to receive instalment payments under
this letter shall be treated as a right to receive a series of separate payments and, accordingly, each instalment payment hereunder
shall at all times be considered a separate and distinct payment. Notwithstanding any provision to the contrary in this letter, if you
are deemed by the Company at the time of your Separation from Service to be a &ldquo;specified employee&rdquo; for purposes of Code Section
409A(a)(2)(B)(i), to the extent delayed commencement of any portion of the severance benefits to which you are entitled under this letter
is required in order to avoid a prohibited distribution under Code Section 409A(a)(2)(B)(i), such portion of your benefits shall not
be provided to you prior to the earlier of (i) the expiration of the six-month period measured from the date of your Separation from
Service with the Company or (ii) the date of your death. Upon the first business day following the expiration of the applicable Code
Section 409A(a)(2)(B)(i) period, all payments deferred pursuant to this paragraph shall be paid in a lump sum to you, and any remaining
payments due under this letter shall be paid as otherwise provided herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Terms
of Employment</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>At-Will
Employment</U>. Notwithstanding any other obligation in this letter, your employment with the Company will be on an &ldquo;at will&rdquo;
basis, meaning that either you or the Company may terminate your employment at any time for any reason or no reason.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Debarment
and Suspension</U>. You agree, assert, and affirm that you are in compliance with United States Federal Executive Order 12549 &ldquo;Debarment
and Suspension&rdquo; and in further compliance with Executive Order 12689, and with Section 2455 of the Federal Acquisition Regulation
as provided in 45 CFR 76&rdquo; Government-Wide Debarment and Suspension (Non-procurement) and Government-Wide Requirements for Drug-Free
Workplace (Grants)&rdquo;, and in further compliance with Office of Management and Budget Memorandum M-87-32, &ldquo;Certification of Non-delinquency
by Applicants for Federal Assistance,&rdquo; that I, to the best of my knowledge and belief:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Am
                                            not presently debarred, suspended, proposed for debarment, declared ineligible, or voluntarily
                                            excluded by any Federal department or agency;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Have
                                            not within a three-year period preceding the Start Date been convicted of or had a civil
                                            judgment rendered against me for commission of fraud or a criminal offense in connection
                                            with obtaining, attempting to obtain, or performing a public (Federal, State, or local) transaction
                                            or contract under a public transaction; violation of Federal or State antitrust statutes
                                            or commission of embezzlement, theft, forgery, bribery, falsification or destruction of records,
                                            making false statements, or receiving stolen property;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Am
                                            not presently indicted for or otherwise criminally or civilly charged by a governmental entity
                                            (Federal, State, or local) with commission of any of the offenses enumerated in paragraph
                                            (1)(b) of this certification;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Have
                                            not within a three-year period preceding the Start Date had one or more public transactions
                                            (Federal, State, or local) terminated for cause or default; and</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Am
                                            not currently delinquent on the repayment of any federal debt.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Confidentiality</U>.
You agree that, by executing this letter, you enter into a Confidentiality Agreement with the company, which is provided in Attachment
2 of this letter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Work
Product Agreement</U>. You agree that, by executing this letter, you enter into a Proprietary Information and Inventions Agreement with
the company, which is provided in Attachment 3 of this letter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --> of 8</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Notification
of Material Changes</U>. You agree to promptly notify Kazia of any material changes in your circumstances, including without limitation
your residential address, your qualifications, professional memberships or certifications, or any of the representations and warranties
contained in this letter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Adherence
to Policies</U>. You acknowledge that you are expected act as a role model for the company and to uphold and champion its policies including,
but not limited to, its policies relating to work health and safety, equal employment opportunities, anti-discrimination, harassment
and bullying. You must also comply with any policies issued by the company, including policies relating to corporate governance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Surveillance
and Data Privacy</U>. The company undertakes continuous and ongoing surveillance in relation to activities carried out on its premises,
or using its property, in order to ensure that its workplaces are safe, and free of risk of harm to all employees and visitors, and also
to protect the company&rsquo;s business interests. In accepting employment with the company, you acknowledge the surveillance set out
in this clause, and consent to such use.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Ownership
of Physical Property</U>. All document, apparatus, equipment and other physical property in any form furnished to you by the Company
or produced by you or others in connection with your employment shall be and remain the sole property of the Company. You shall return
to the Company all such documents, materials and property as and when requested by the Company, except only (i) personal copies of records
relating to my compensation; (ii) if applicable, personal copies of any materials evidencing shares of the Company&rsquo;s capital stock
purchased by you and/or options to purchase shares of the Company&rsquo;s capital stock granted to you; (iii) your copy of this Agreement
and (iv) your personal property and personal documents that you bring with you to the Company and any personal correspondence and personal
materials that you accumulate and keep at the Company&rsquo;s office during your employment. Even if the Company does not so request,
you shall return all such documents, materials and property upon termination of your employment, and, except for your personal documents,
you will not take with you any such documents, material or property or any reproduction thereof upon such termination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Obligations
at Termination</U>. Upon termination of your employment for any reason, you must, at the Company&rsquo;s request, cooperate with the
company and render all reasonable assistance in the prosecution or defence of legal claims and proceedings. You must execute all documents
and give all reasonable assistance required to relinquish offices held on behalf of the Company, and to allow the Company to protect
intellectual property and confidential information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Non-Solicitation</U>.
During your employment, and for a period of twelve (12) months after termination, you may not directly or indirectly solicit, induce,
recruit or encourage any of the Company&rsquo;s employees or consultants to terminate their relationship with the Company, or attempt
any of the foregoing, either for yourself or any other person or entity. One approved exception is Jamie Lynn Coulter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conditions
of Employment</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Proof
of Right to Work</U>. For purposes of federal immigration law, you will be required to provide to the Company documentary evidence of
your identity and eligibility for employment in the United States. Such documentation must be provided to us within three (3) business
days of your date of hire, or our employment relationship with you may be terminated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Background
and Credit Review</U>. You agree to and will promptly complete any necessary documentation to allow a personal background and credit
review. All information will be held strictly confidential but will be used to finally qualify you for this position. Satisfactory passage
of this check must be completed within seven (7) business days of your date of hire, or our employment relationship with you may be terminated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Warranties</U>.
In accepting this offer of employment, you warrant that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
                                            will not be in breach of any agreement with, or obligation owed to, any third party; and</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
                                            have disclosed all material information to Kazia which may be relevant to the company&rsquo;s
                                            decision to offer you employment; and</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
                                            representations you have made as to your qualifications, skills, experience, industry knowledge,
                                            business influence, contacts, and employment history are true and correct and complete.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are all delighted to be able to extend you this offer and look forward to working with you. To indicate your acceptance of the Company&rsquo;s
offer, please sign and date this letter in the space provided below, and separately on Attachment 2 and Attachment 3. Please return the
signed documents to the company. This letter, together with its Attachments, set forth the terms of your employment with the Company
and supersede any prior representations or agreements, whether written or oral. This letter may not be modified or amended except by
a written agreement, signed by the Company and by you.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --> of 8</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>




<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yours
    sincerely,</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 30%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
    and on behalf of Kazia Therapeutics:</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    John Friend</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Dr.
    John Friend</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Accepted
    and agreed by:</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 30%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    James Levine</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">James
    Levine</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Date:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --> of 8</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ATTACHMENT
1</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PARTICULARS
OF EMPLOYMENT</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Position</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 78%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Position
    Overview</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Chief Financial Officer will serve as a strategic and operational partner to the CEO, leading all aspects of finance, capital markets,
    investor-facing financial communications, SEC and Nasdaq compliance, audit management, forecasting, treasury, and corporate finance
    strategy. In addition to overseeing the company&rsquo;s financial operations and controls, the CFO will play a highly visible external
    role supporting financing initiatives, institutional investor engagement, banking relationships, strategic transactions, and long-term
    corporate positioning. Given Kazia&rsquo;s expanding clinical and corporate development activities, the role requires a forward-facing
    executive capable of operating at the intersection of biotech finance, capital markets, and strategic growth, while working collaboratively
    across investor relations, business development, and operational functions to support the company&rsquo;s next phase of expansion.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Manager</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CEO</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Place
    of Work</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Home-based</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Commencement
    Date</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
    1, 2026</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Base
    Salary</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US$
    475,000 per annum (paid as $39,583.33 per calendar month)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Target
    Bonus</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">40%
    of your annual base salary (prorated for 2026)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>LTI
Options Grant</B></FONT></P>
                                                         <P STYLE="margin-top: 0; margin-bottom: 0">(subject to Board approval)</P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">200,000 (two hundred thousand) ADS options</FONT></P>
                                                         <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
                                                         <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1/3 of ADS options to vest upon commencement of employment. Grantee to forfeit all options upon a voluntary departure prior to the completion of year 1. The remaining 2/3 to vest in equal yearly instalments thereafter.</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Health
    Insurance</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Health, Dental, and Vision</FONT></P>
                                                         <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
                                                         <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">100% of premium for employees and a proportion of premium, not less than 50%, for dependents</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>401(k)
    Plan</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company
    sponsored Safe Harbor 401k Plan with Company Match (100% for first 4% and 50% for next 2%). Employees are eligible to participate
    after one pay cycle. Matching is immediate with no vesting period.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Paid
    Time Off (PTO)</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20
    days per calendar year</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --> of 8</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ATTACHMENT
2</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONFIDENTIALITY
AGREEMENT</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the purposes of this Agreement, Confidential Information means information which came to the employee&rsquo;s knowledge in the course
of, or as a result of, their employment including, but not limited to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            business or affairs, financial information, intellectual property, business plans, research
                                            and development, and sales and marketing information of the Company;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">unpatented
                                            molecular structures, manufacturing processes, assay methodologies, preclinical or clinical
                                            data;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">information
                                            which would reasonably be considered to be of a business sensitive nature;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">trade
                                            secrets and confidential information and know-how of the Company;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">information
                                            regarding investments, investment opportunities, investment strategies and investment research
                                            of the Company; and</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">confidential
                                            information of a third party that has been shared with Company.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Confidential
Information will not include information which is or becomes readily available in the public domain otherwise than as a result of the
breach of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
employee must not use or disclose this Confidential Information during and after their employment, and must take all reasonable steps
to prevent the unauthorised disclosure of the Confidential Information, except in the following circumstances:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            Company has given its prior written consent; or</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
                                            the proper course of performing their duties and for the benefit of the Company; or</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
                                            the extent required by law.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Without
limiting the generality of the above, the employee must not disclose Confidential Information to other employees of the Company unless
these employees are authorised by the Company to receive this information and need to know this information to perform their duties to
the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
employee must immediately notify the Company if the employee suspects or becomes aware that Confidential Information has been improperly
used, copied or disclosed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
employee must not copy or remove from the Company&rsquo;s premises any document which contains Confidential Information except for the
purpose of properly performing the duties of the position and for the benefit of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
employee must provide assistance reasonably requested by the Company in relation to proceedings against any person for unauthorised use,
copying or disclosure of Confidential Information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD COLSPAN="2"><B>Accepted and agreed by:</B></TD>
  <TD><B>&nbsp;</B></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 5%">&nbsp;</TD>
  <TD STYLE="width: 35%">&nbsp;</TD>
  <TD STYLE="width: 60%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid"></TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD COLSPAN="2">James Levine</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>Date:</TD>
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --> of 8</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ATTACHMENT
3</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PROPRIETARY
INFORMATION AND INVENTIONS AGREEMENT</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
exchange for my becoming employed (or my employment being continued), or retained as a consultant (or my consulting relationship being
continued), by Kazia Therapeutics, or any of its current or future subsidiaries, affiliates, successors or assigns (collectively, the
&ldquo;Company&rdquo;), and for any cash and equity compensation for my services, I hereby agree as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assignment
of Inventions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Without
                                            further compensation, I hereby agree promptly to disclose to the Company, all Inventions
                                            (as defined below) which I may solely or jointly develop or reduce to practice during the
                                            period of my employment or consulting relationship with the Company which (i) pertain to
                                            any line of business activity of the Company, (ii) are aided by the use of time, material
                                            or facilities of the Company, whether or not during working hours or (iii) relate to any
                                            of my work during the period of my employment or consulting relationship with the Company,
                                            whether or not during normal working hours (&ldquo;Company Inventions&rdquo;). During the
                                            term of my employment or consultancy, all Company Inventions that I conceive, reduce to practice,
                                            develop or have developed (in whole or in part, either alone or jointly with others) shall
                                            be the sole property of the Company and its assigns to the maximum extent permitted by law
                                            (and to the fullest extent permitted by law shall be deemed &ldquo;works made for hire&rdquo;),
                                            and the Company and its assigns shall be the sole owner of all patents, copyrights, trademarks,
                                            trade secrets and other rights in connection therewith. I hereby assign to the Company any
                                            rights that I may have or acquire in such Company Inventions.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 46.35pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
                                            have provided to the Company, prior to my engagement, a complete list of all Inventions,
                                            if any, made by me prior to my employment or consulting relationship with the Company that
                                            are relevant to the Company&rsquo;s business, and I represent and warrant that such list
                                            is complete. If no such list is provided, I represent that I have no such Inventions at the
                                            time of signing this Agreement. If in the course of my employment or consultancy (as the
                                            case may be) with the Company, I use or incorporate any Invention in which I have an interest
                                            into a product or process of the Company, the Company is hereby granted a nonexclusive, fully
                                            paid-up, royalty-free, perpetual, irrevocable worldwide license of my interest to use and
                                            sublicense such Invention without restriction of any kind.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 46.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTICE
REQUIRED BY REVISED CODE OF WASHINGTON 49.44.140:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
assignment of Inventions required by this Agreement does not apply to an Invention for which no equipment, supplies, facility or trade
secret information of the Company was used and which was developed entirely on the employee&rsquo;s own time, unless (a) the Invention
relates (i) directly to the business of the Company or (ii) to the Company&rsquo;s actual or demonstrably anticipated research or development
or (b) the Invention results from any work performed by the employee for the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Further
Assistance and Power of Attorney</U><B>. </B>I agree to perform, during and after my employment or consulting relationship, all acts
deemed necessary or desirable by the Company to permit and assist it, at its expense, in obtaining and enforcing the full benefits, enjoyment,
rights and title throughout the world in the Inventions assigned to the Company as set forth in Section 4 above. Such acts may include,
but are not limited to, execution of documents and assistance or cooperation in legal proceedings. I hereby irrevocably designate the
Company and its duly authorized officers and agents as my agent and attorney-in fact, to execute and file on my behalf any such applications
and to do all other lawful acts to further the prosecution and issuance of patents, copyright and mask work registrations related to
such Inventions. This power of attorney shall not be affected by my subsequent incapacity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Inventions</U>.
As used in this Agreement, the term &ldquo;Inventions&rdquo; means discoveries, developments, concepts, designs, ideas, know how, improvements,
inventions, trade secrets and/or original works of authorship, whether or not patentable, copyrightable or otherwise legally protectable.
This includes, but is not limited to, any new product, machine, article of manufacture, biological material, method, procedure, process,
technique, use, equipment, device, apparatus, system, compound, formulation, composition of matter, design or configuration of any kind,
or any improvement thereon.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Survival</U>.
This Agreement (a) shall survive for a period of five years beyond the termination of my employment by or consulting relationship with
the Company, (b) inures to the benefit of successors and assigns of the Company and (c) is binding upon my heirs and legal representatives.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Injunctive
Relief</U>. I acknowledge that violation of this Agreement by me may cause irreparable injury to the Company, and I agree that the Company
will be entitled to seek extraordinary relief in court, including, but not limited to, temporary restraining orders, preliminary injunctions
and permanent injunctions without the necessity of posting a bond or other security and without prejudice to any other rights and remedies
that the Company may have for a breach of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD COLSPAN="2"><B>Accepted and agreed by:</B></TD>
  <TD><B>&nbsp;</B></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 5%">&nbsp;</TD>
  <TD STYLE="width: 35%">&nbsp;</TD>
  <TD STYLE="width: 60%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid"></TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD COLSPAN="2">James Levine</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>Date:</TD>
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --> of 8</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B><A NAME="a_002"></A>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Kazia Therapeutics Appoints James Levine as
Chief Financial Officer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>SYDNEY, Australia, June 2, 2026 </B>&ndash;
<U>Kazia Therapeutics Limited</U> (NASDAQ: KZIA) (&ldquo;Kazia,&rdquo; &ldquo;Kazia Therapeutics&rdquo; or the &ldquo;Company&rdquo;),
a clinical-stage oncology company advancing therapies designed to reprogram cancer biology and overcome treatment resistance, today announced
the appointment of James Levine as Chief Financial Officer, effective June 1, 2026. Mr. Levine brings more than two decades of experience
across investment banking, executive and financial leadership at publicly traded biotech companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&ldquo;James has built an impressive career leading
financial strategy, strategic transactions and major pharmaceutical collaborations, following an extensive career in investment banking,&rdquo;
said Dr. John Friend, CEO, Kazia Therapeutics. &ldquo;As we advance paxalisib and progress our pipeline, James' expertise will be central
to helping us capitalize on that momentum and continue building long-term value for patients and shareholders.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Most recently, Mr. Levine served as Chief Financial
Officer of Cardiff Oncology, a clinical-stage oncology company developing a PLK1 inhibitor therapy for solid tumors. Prior to Cardiff
Oncology, Mr. Levine served as CFO of Cidara Therapeutics, an antifungal and antiviral biotech company, where he led the financial structuring
of a $568 million licensing collaboration with Mundipharma and a $780 million global partnership with Janssen Pharmaceuticals (Johnson
&amp; Johnson). He also served as CEO of Verenium Corporation, an industrial biotech company, where he executed major asset sales for
total proceeds of approximately $200 million, as well as Sapphire Energy, a human nutrition-focused biotech.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Earlier in his career, Mr. Levine spent 12 years
at Goldman Sachs &amp; Co. as a Managing Director advising pharmaceutical and biotech clients across the U.S. and Europe on financings,
mergers and acquisitions and strategic transactions, including landmark deals such as the Glaxo Wellcome and SmithKline Beecham merger.
Mr. Levine holds a Master of Business Administration degree from The Wharton School at the University of Pennsylvania.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&ldquo;I am very excited to be joining Kazia as
the Company advances paxalisib across multiple indications and builds out a promising pipeline targeting novel mechanisms of
treatment resistance,&rdquo; added Mr. Levine. &ldquo;I look forward to working closely with the management team to help translate
Kazia&rsquo;s scientific progress into strategic and financial outcomes as we approach what we expect to be a period of meaningful
clinical and strategic milestones for the Company.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Kazia Therapeutics</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Kazia Therapeutics Limited (NASDAQ: KZIA) is an oncology-focused drug
development company, based in Sydney, Australia. The Company&rsquo;s lead asset, paxalisib, is an investigational brain penetrant inhibitor
of the PI3K/Akt /mTOR pathway, which is being developed to treat multiple forms of cancer. Licensed from Genentech in late 2016, paxalisib
is or has been the subject of 10 clinical trials. A completed Phase 2/3 study in glioblastoma (GBM-Agile) was reported in 2024, and discussions
are ongoing for designing and executing a pivotal registrational study in pursuit of a standard approval. Other clinical trials involving
paxalisib are ongoing in advanced breast cancer, brain metastases, diffuse midline gliomas, and primary central nervous system lymphoma,
with several of these trials having reported encouraging interim data. Paxalisib was granted Orphan Drug Designation for glioblastoma
by the U.S. Food and Drug Administration (FDA) in February 2018, and Fast Track Designation (FTD) for glioblastoma in August 2020. Paxalisib
was also granted FTD in July 2023 for the treatment of solid tumor brain metastases harboring PI3K pathway mutations in combination with
radiation therapy. Additionally, paxalisib was granted Rare Pediatric Disease Designation and Orphan Drug Designation by the FDA for diffuse
intrinsic pontine glioma in August 2020 and for atypical teratoid / rhabdoid tumors in June 2022 and July 2022, respectively. Kazia is
also developing EVT801, a small molecule inhibitor of VEGFR3, which was licensed from Evotec SE in April 2021. In addition to its clinical-stage
programs, Kazia is advancing NDL2, a potentially first-in-class intracellular PD-L1 protein degrader program targeting a newly identified
mechanism of immunotherapy resistance and metastatic progression, as well as MSETC, a potentially first-in-class SETDB1 inhibitor program
intended to restore immune signaling in tumors that have become resistant to immunotherapy, including checkpoint inhibitors. Both programs
are currently in preclinical development. For more information, please visit www.kaziatherapeutics.com or follow us on X @KaziaTx.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Forward Looking Statements </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This announcement may contain forward-looking statements, which can
generally be identified as such by the use of words such as &ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;estimate,&rdquo; &ldquo;future,&rdquo;
&ldquo;forward,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;expect,&rdquo; &ldquo;plan,&rdquo; &ldquo;believe,&rdquo; &ldquo;potential,&rdquo;
or other similar words. Any statement describing Kazia's future plans, strategies, intentions, expectations, objectives, goals or prospects,
and other statements that are not historical facts, are also forward-looking statements, including, but not limited to, statements regarding:
the Company&rsquo;s expectations regarding its pipeline strategy and future clinical and strategic milestones; the anticipated contributions
of Mr. Levine to the Company's business; and Kazia&rsquo;s plans to advance paxalisib and its broader oncology pipeline. Such statements
are based on Kazia's current expectations and projections about future events and future trends affecting its business and are subject
to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking
statements, including risks and uncertainties associated with: the development of early stage therapeutic programs; the conduct of clinical
trials, including the ability to enroll patients and achieve anticipated enrollment targets; the preliminary nature of data from a small,
open-label clinical study, which may not be predictive of later-stage clinical results; risks related to regulatory approvals; risks related
to Kazia's reliance on third-party collaborators and clinical trial sites; risks related to the Company's ability to obtain, maintain
and protect its intellectual property; risks related to the impact of global economic conditions; and risks related to Kazia's ability
to maintain compliance with the applicable NASDAQ continued listing requirements and standards. These and other risks and uncertainties
are described more fully in Kazia's Annual Report on Form 20-F filed with the SEC, and in subsequent filings with the United States Securities
and Exchange Commission. Kazia undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information,
future events, or otherwise, except as required under applicable law. You should not place undue reliance on these forward-looking statements,
which apply only as of the date of this announcement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Media Contacts </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Michaela Fawcett / Molly Crawford</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">KCSA Strategic Communications</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">mfawcett@kcsa.com / mcrawford@kcsa.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">###</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>ea029311505_img1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ea029311505_img1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  \ ,0# 2(  A$! Q$!_\0
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M ET,<C11E8G D(<@%"":X95:E3DA!N$Y345HGKHMI)E3DJ<7*2=DKO1[6O\
MC\S=,A )VCCK\Q]_]GV-*) 55B,;AD#/T/MZ\\<<U_-MXJ_X.3OV9O"WB#7_
M  [>?"/XG>?X>UW5-!OKU1I,D,L^DZC/8RR00"Z$OV>4PYC=\2#.7C (%:7@
M;_@XO^ OQ*\<^"?AOX-^!GQ;U+Q=XY\6:%X4\.V,-O9/%/<Z_>QV$)E9F1E6
M#S/ML\R%XXK:"42$$@CUH8'%^RE/D<XTHWE)6O9*[>R3OY;:+JCGIXW#59N$
M:JC)=&GIY)O1WZ,_HW\U,')P0<$=\]?Y<_3FH9+I(]WRNVW& JDEL]U !) '
M)-8.GW=[.F+M%CGC.VXC8)O,H4?O4,<DB+"5.%4,Q!!RW-?G%_P4&_X*9_#W
M_@GC_P *\NOB1X.\4>,[3XE7NLV6BKX0BLS<6)T&S@OM2-XUY/&"I@E_=K&&
M;(S@D&N'#2KXFJX0I-QO9:/F[*^G?5[[F]6I&C%2F_=:3376^G]=%W/U#1MZ
M*^,!AD<YX_(<^M.KP7]G7XY:1^T3\&/AU\;/#6GWFD^'_B/X=A\1Z1HVJ(J:
MO;6UTH>""[*'RA.J[C(5!7!7G.:]XR2H)^4D D9&03U&>F>V?7FMYJ4'*+5I
M1;5O->GG\_F5%J24EM))I[Z/7=:?<QW/M^?_ -:F%P&"D=3@'U.,_IWQFOE[
M]I[]IGPW^RG\#_B-\=_'^;OPW\/_  ]J&M/86!A6\UF_6Y^S:7H5BQD8_;+F
M5D5CL8X);:N"*U/V=_V@?"W[2GP@^%OQQ\%7"CPQ\3/#>G:_80$BXGTV^D@D
M;5O#NH,C8BOM,N%>WF9D7#P."HW  =+$1HJO.FU3<N5.V[\K]KIZZ[V%&=.5
M5T%./M(QYG&_37_+T3W/I"BD5@P##H>E%(H_.C]JS]IJS^$'BJ'P?+X7N/$$
M&JZ?+J&L.&:?=8S2I:M;V=HH\J:>.W-P5MY=P=O+#9W@FS;7WP"_9>^&NL?'
M=M);PKI&MZ9973PK!<?VK>?VN5FL-*MH2[QP7@DFVR1LH\M\H,(NVN7^,'QJ
M^$^N?M!:?\)O%G@8:S<6?B6UT"/Q+>1;H+'6[R."[CME!3,J_+$^-^,Y 7@Y
MYG]N7XW?"'X2^$M#^%OQ,\'ZIXVL/B?'";'0H(H+>WLXM)O#;C7K223 L[JP
M>6-[:W0(TOEI)UZ^[F>*67Y''#0YXQQ%*E5G!?#)SC&I=QCHY.3NGHTY7:=C
M\]X5R7^WO$.6-Q_)CLKPN(Q%"53"1BJ]!TZM6+IRE9^_#D:FFM8P>M]3YR\=
M_"?5/^"@/B'X4?M)?!_XH:KX<\):,\>D:GX9O5U!-1T"_P##_B:6>[N;.:VO
MHD,]U:0R08D5TRP)1NA^UO$7[$WPO\7?%?0OCCKR:I>>-M .CRR)=W4::;K<
M_AV 2:??ZE9?*@NX CN]Q;K'<2R1S!F(* >C_ KP?\-?A9\%M'A^'NGKIO@G
M^QV\76%K\S3W']H02ZI/=:@J!5FN<I+)O=@#(3R<YK\R_$O[=WQ@N?$.MZEH
M2Z<NB6=Y/!::,]K,)-0L;:]N+>XDD1E >:2TM),DC(49,40/F-XO#O"V8<3Q
MGB<(G.-!2J-R6L8T_??GLM&UYZ'VO'7BGA.!Z]/!3ING@4U0P]>,%&I-U&X1
MHSFN5N-32$U9*6J?1OTO4_V</%/P1_:3\4?M>^+OB??VWPZTV:]\37NFV=Y=
M/>W&GWUE,8-"^SM(T+0F8QB,2(1$.05!S7T]\/\ XA_ ;]N?X9W6N6>F3ZGI
MVE:O/::UHVM(W]HZ1*TDI#.PVIOOK9G$;Q'>B$[2,FO:='O_  M\<O@:DVN:
M?!<^&_&?AR&UU.RO(3NDLKN#[/<L) I9?*7S%MBHZ@*#7PG^P=\<O@))\2_&
M'[.GPC\#:GX>M](O-6U1M5OKN:_36;G0IQ9M.[[,%82Q2(LQ*1YXXKQZ/U[(
M\\GA9RER5*B@YQE+^=IQ3YK:]==5JGT/0QU3#^(G"5/'2AAX2IX9NE&=.FZ<
M4H*44Z<HM.R4K)M6U>C23]7^"_[46DS_ !5@^"7A[P?+I'AG2KK5_#VCW=O,
MUU<6!T8 ^=>VLJ'[-:NFU8').^16R 17Z06'^D+YLDRW!546.4,V\\-YGF#A
M<LP& . .@P:_-WQY\<_A3\+/V@K;PG!\-[63Q=J-W8VFL>(],@CMKB'^VI/,
MBN5Q&'GDD9MDYZ[%&XD<#]&-'"I:A$<21\2)(!M+)*!(B.G\#1*VT@#!SZ\5
M]+G4%+V.(CI>E.3LKVE;W6^S;O;FBM^I^<<&U\3&IC\!4QE*M3PE5T84X)-1
M47*-H*-E"#5VDMFK-+K_ "%?\'1D]XGC3]D&&R%LOVSPK\6(;UY!^^BMWU#P
MW&LL+ !ED :<(R$-O(8995(_.[X[_MU?$S]JOX%_L5_\$]OV=+35I=&T?X?>
M O!GBRQ@\NTE\;_$01R64%K,[S0K<:%IJCSK^&X^26YCE9D=FR?T"_X.CKA(
M/'O['S1O&MV/!7QADC%RVV!F2_\ #BV@+'@2K*SF)B<@\CDU^?'[37["OC+]
MGC]GK]C#_@H/\ SJ^GZ+XF^''PZ\1^*[ZUWS2^!OB.T,E[%K]PL)5AI6J2(S
MRW)P!)(V_P!3[V&="&6994JVC*:G*,^7WG5UL[K7F46TG?:]K,]?&1E.I5IP
MDXQY&YQCLUSQ7O*ZTNEONWMNW_7-_P $T_V ?"/[!?P$LO"MO-;ZU\6?%L!U
MGXJ^-%CBC;5?$EW%&5\.Z7N$C0Z'HQ#VUI;AC'&Z2.N"PV_I["ICMHD"[3'"
M%"EO,*L5RP,G60[NK$G=C))SS^47_!++_@H/X4_;M^"5E?75Q8:3\:/ UO::
M%\3_  S'/$CS7L%HD:^)M'@9MTEAJKE9_-V_,\CKD<"OU84LJ1HRMDQ!0HPA
MC81[6,@!8*"<E6R-O)'2OC\TCBYXVK.K.;C>$8MR<KMR6D=%T>W1=;K7W<K]
MG'"PC"$8\C;FHQY;Z7]Y)):=[^5];'P9_P %'_VL[;]C?]D?XL?&&>X@;Q,/
M#C>%O 6ESS1Q7&H>./$22Z9IS6R$!G33VN%U";:"JQ0,S  '/\&'[%O[4?Q-
M_9!_:E^#/[4^OQZHN@^,/$>O6_BO4[ZVG6S\9^"M6OQ;^/KB"[E0K>OH]S=2
MWT+*[2&6V5MPR<_I?_P7Y_:U?XX?M#>'_P!EOPAJAUSP=\"K6ZOO$_V*]?4(
M]3^)NK6"!XIIXV9;EO#VBM%$J%&>/49+@JNYL5\-?M#_ +7?PV^//[*_[,G[
M-OAS]GS6_ 6I_L[I/;Z7XX>"754\1)J-E)%XGM+@?8TWQ:OJ1%W.\TA6"0!7
M([?799AHQPD8>SYG73E)RM=<L5%73U:BNNGQW=TF?/9KC93Q2E"4H*A)P2C*
M4>=.2;U5M+KN^9Z6Z'^B?X/\30>--(T3Q5H.J6^J^$O$^AZ?K_A_5(6A<W^G
MZO;PWVFRPB(;?L[V$BR,S983F2,GY,#K-5ABFLI$DC6=FCD"ABBY;R760IY@
MVE_+9SMYRN<\"OY\/^" O[7<_P ;?V=)_@7XKUV.Y^(O[-UQ%X7*R3O%>:U\
M-;^-YO!]TL<C%G70I9+K2[I<8BD^S)N 5:_?W6S(L-B8Q/*ZW<<(2/;_ *RX
MCEB65Y6YCCC+YF.<M#Y@;K7R^+P_U7%6:C+GJN,6GK&\DMU%KX>J6GJ?0X3%
M+&4(Q5_=IQE)N.[MK>]MFF]=+=6?@I_P4>_9?_X)V_LB_LV_%']HK6/@!X%N
MO&%U%J-GX*MKMB7\1?$/QO&]O:7;QFY#S;-0E-Y<R!&6%49@JQU^5_\ P;V?
ML?3?$7XR^)_VN?&6D2-X+^%<T^B?#IIK7=97OC[Q%&BZO?Z*K((WM_"EK.;&
M)R'CAED,JJLR!AY3_P %T_VI5_:9_:4\,_LU>"];M;GX>_!K7-(\+OJQDC'A
MF_\ BAK-W]E\1ZI>2AS!<:9X4AF-GAN+4QL%VG-?TJ_L&^)_V._V:?@9\(OV
M8?A_\?\ X8:UXCT;3X8KN&'Q)8W&H>(_&>NO;WWB&YMH(92S->7<C0PDY9HD
M51M"D5])76-R[+X.\YPQ5.7*KMVIM;2332VM9J]VWHT>#0GA*^95(W]G.ZC*
M,79-K3FDU;>T;7M96Z;_ *@Z?;1BS<%GD"/,Z^8WSQ_O2/)+J0[+'VWLQ[<8
MQ7\H7_!TC<O:>'OV0'B56$?B+XG,(MBM@MHFD1F121D;5D?=MY(/S=!7]9-@
MJK%.BHB#[1.3&G*JS,7.#_$'W>8"."6)X/7^2O\ X.CG)TK]D50TC*-9^)9F
M$:;UAQI>E %QCH^,8/&$P< U\_E+E]:;=X^]=I+9R5[>6CT^[?0]S'1<,/&"
M=U&+2;=[I?#U?>^_=G[Q_P#!+W==_L"?LI2S,&:7X3Z,ZS(A'FQR6[*69U90
MC8&T,NW[@"X.2?OR2010PHA+#!1><D[%(49;)8D@=<D\DY/-? '_  2X"_\
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MM$D%M<S><\4@'F*AVYR17T@EG$N<M*YXY>0L1AF88/'0MCZ #M3#:11CY#(
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MZ&D\J/G ()[@D'TSUZTUH4,;H<G<K*6S\PRI7(;J#@G!['F@!X=3G!Z8['N
<PQ^!%%"QJJJH!PJA02220H"C)[G &3WHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ea029311505_img2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ea029311505_img2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !4 /0# 2(  A$! Q$!_\0
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M)K2XL(2\,I7*[QUP?:E\/Z#-ICS27+H2Z[0JG(Q[U-I>AV>C-)=^>7^7[[X
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M=BJMC;J8RL2@QDE".Q/6D_L^U\KRO(39NW8QWSG/YU;HHNPY8]B%((HY'D5
M'DQN/KBH7TRSDN?M#0*9L@[^^1TJY11=@XI]"G+IEG/.L\L"/*O1B*F>WBDD
MCD9 7CSM/IFIJ*+L.5=B 6T2R22!!OD #GU Z5#!I=E;2M)#;QH[#!(%7:*+
ML.5=BI;:=:6CL\$"QLW!(]*MT44-WW&DEL%%%%(84444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
24444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
